Abstract
The immune system can be a potent defense mechanism against cancer. Especially CD8+ cytotoxic T lymphocytes (CTL) have a great killing capacity towards tumor cells. However, their potential is often dampened by immune suppressive mechanisms in the tumor microenvironment. Co-inhibitory molecules (CIM) expressed by tumor cells, immune cells and stromal cells in the tumor milieu can severely hamper CD8+ T-cell responses against cancer cells. Today, a variety of co-inhibitory molecules, including PD-1, CTLA-4, LAG3, BTLA, Tim-3 and CD200R, have been implicated in tumor escape from CTL attack. Sustained signaling via these CIM can result in functional exhaustion of T-cells, a process in which the ability to proliferate, secrete cytokines and mediate lysis of tumor cells is sequentially lost. In this chapter, we discuss the influence of co-inhibitory pathways in suppressing CD8+ T-cell function in various immune settings. These include the natural immune surveillance by CTL against tumor cells, or in therapeutic settings like allogeneic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy. In addition, we discuss exciting pre-clinical and clinical data of immunotherapeutic approaches interfering with negative co-signaling, either as monotherapy or in conjunction with vaccination strategies. Numerous studies indicate that co-inhibitory signaling limits the clinical benefit of current CTL-based therapies. Therefore, interference with CIM is an attractive immunotherapeutic intervention for cancer therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.